A significant positive correlation between serum sclerostin and BMD of the lumbar spine was also observed in postmenopausal breast cancer patients treated with aromatase inhibitors, where sclerostin levels reportedly increased 46% due to treatment19. Here, SOST is linked to breast cancer.